Show simple item record

dc.contributor.authorSchuessler, Andrea
dc.contributor.authorSmith, Corey
dc.contributor.authorBeagley, Leone
dc.contributor.authorM. Boyle, Glen
dc.contributor.authorRehan, Sweera
dc.contributor.authorMatthews, Katherine
dc.contributor.authorJones, Linda
dc.contributor.authorCrough, Tania
dc.contributor.authorDasari, Vijayendra
dc.contributor.authorKlein, Kerenaftali
dc.contributor.authorSmalley, Amy
dc.contributor.authorAlexander, Hamish
dc.contributor.authorG. Walker, David
dc.contributor.authorKhanna, Rajiv
dc.date.accessioned2017-05-03T14:17:56Z
dc.date.available2017-05-03T14:17:56Z
dc.date.issued2014
dc.identifier.issn00085472
dc.identifier.doi10.1158/0008-5472.CAN-14-0296
dc.identifier.urihttp://hdl.handle.net/10072/66730
dc.description.abstractGlioblastoma multiforme (GBM) is one of the most aggressive human brain malignancies. Even with optimal treatment, median survival is less than 6 months for patients with recurrent GBM. Immune-based therapies have the potential to improve patient outcome by supplementing standard treatment. Expression of human cytomegalovirus (CMV) antigens in GBM tissues provides the unique opportunity to target viral antigens for GBM therapy. Here, we report findings of a formal clinical assessment of safety and potential clinical efficacy of autologous CMV-specific T-cell therapy as a consolidative treatment for recurrent GBM. From a total of 19 patients with recurrent GBM, CMV-specific T cells were successfully expanded from 13 patients (68.4%), 11 of whom received up to four T-cell infusions. Combination therapy based on T-cell infusion and chemotherapy was well tolerated, and we detected only minor adverse events. The overall survival of these patients since first recurrence ranged from 133 to 2,428 days, with a median overall survival of 403 days. Most importantly, 4 of 10 patients that completed the treatment remained progression free during the study period. Furthermore, molecular profiling of CMV-specific T-cell therapy from these patients revealed distinct gene expression signatures, which correlated with their clinical response. Our study suggests that a combination therapy with autologous CMV-specific T cells and chemotherapy is a safe novel treatment option and may offer clinical benefit for patients with recurrent GBM.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom3466
dc.relation.ispartofpageto3476
dc.relation.ispartofissue13
dc.relation.ispartofjournalCancer Research
dc.relation.ispartofvolume74
dc.rights.retentionY
dc.subject.fieldofresearchMedical and Health Sciences not elsewhere classified
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode119999
dc.subject.fieldofresearchcode1112
dc.titleAutologous T cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorWalker, David G.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record